다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of cutaneous laser therapy, v.2 no.3, 2000년, pp.151 - 156
Clark, S M (Department of Dermatology, University Hospital of Wales, Cardiff, Wales, UK) , Mills, C M (Department of Dermatology, The Royal Gwent Hospital, Newport, Wales, UK) , Lanigan, S W (Department of Dermatology, The Princess of Wales Hospital, Bridgend, Wales, UK)
BACKGROUND : Few therapies are currently available to treat keratosis pilaris atrophicans (KPA), a spectrum of disorders which includes ulerythema ophryogenes and atrophoderma vermiculata. OBJECTIVE : To evaluate the response of KPA to treatment with the pulsed dye laser (PDL) with regard to improvements in erythema and skin roughness, treatment tolerability, and side effects. METHODS : Treatment of all facial areas involved with KPA with the PDL at 585 nm was evaluated in 12 patients. Prior to and after each treatment skin erythema was estimated using an erythema meter, and skin roughness was analysed using micrometer evaluation of a skin surface biopsy taken from the same mapped area and anaysed by computer to calculate the roughness profile. RESULTS : Patients received 2 to 8 treatments with the PDL with energies ranging from 6.0 to 7.5 J/cm 2 . Clinical improvement was noted in all patients with significant reduction in erythema scores. Pre-treatment scores ranged from 4 to 13 (mean 8.3) and post-treatment 0 to 8 (mean 3.1) ( P < 0.05). Improvements in skin roughness were clinically apparent in all but two patients, but these were not significant on evaluation of skin surface biopsies. Treatment was generally well tolerated, and side effects other than local pain during treatment were very few. CONCLUSION : PDL treatment appears to be a safe and effective treatment for the erythema associated with KPA but does not give significant improvement in associated skin roughness.
Pediat Dermatol McHenry PM 202 7 1990 10.1111/j.1525-1470.1990.tb00283.x
Pediatr Dermatol Snell JA 77 7 1990 10.1111/j.1525-1470.1990.tb01080.x
Postgrad Med J Burton JL 595 68 1992 10.1136/pgmj.68.801.595-a
Pediatr Dermatol Zouboulis CC 172 11 1994 10.1111/j.1525-1470.1994.tb00575.x
J Am Acad Dermatol Burnett JW 437 18 1988 10.1016/S0190-9622(88)70065-1
10.1001/archderm.131.5.556
Br J Dermatol Layton AM 645 129 1993 10.1111/j.1365-2133.1993.tb11849.x
J Am Acad Dermatol Reyes BA 1142 23 1990 10.1016/0190-9622(90)70348-L
J Dermatol Surg Oncol Garden JM 321 19 1993 10.1111/j.1524-4725.1993.tb00353.x
Br J Dermatol Seukeran DC 725 136 1997 10.1111/j.1365-2133.1997.tb03659.x
J Dermatol Surg Oncol Ruiz-Esparza J 1000 19 1993 10.1111/j.1524-4725.1993.tb00991.x
J Dermatol Surg Oncol Lowe NJ 522 17 1991
J Dermatol Treat Mills CM 237 6 1995 10.3109/09546639509086851
Lasers Surg Med Ros AM 331 19 1996 10.1002/(SICI)1096-9101(1996)19:3<331::AID-LSM8>3.0.CO;2-T
Int J Cosmet Science Pearce AD 63 12 1990 10.1111/j.1467-2494.1990.tb00521.x
Br J Dermatol Forton F 650 128 1993 10.1111/j.1365-2133.1993.tb00261.x
Br J Dermatol Wlotake U 475 134 1996 10.1111/j.1365-2133.1996.tb16233.x
Dermatol Surg Lowe NJ 179 21 1995
Lasers Surg Med Kurwa H 37 8 1996
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.